Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD
In smoking-induced chronic obstructive pulmonary disease (COPD), various comorbidities are linked to systemic inflammation and infection-induced exacerbations. The underlying mechanisms are unclear but might provide therapeutic targets. T-cell activity is central in systemic inflammation and for inf...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/13/7187 |
id |
doaj-7e542ae4dcb545eaa77e5c9b31226d46 |
---|---|
record_format |
Article |
spelling |
doaj-7e542ae4dcb545eaa77e5c9b31226d462021-07-15T15:38:26ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-01227187718710.3390/ijms22137187Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPDKaschin Jamal Jameel0Willem-Jakob Gallert1Sarah D. Yanik2Susanne Panek3Juliane Kronsbein4David Jungck5Andrea Koch6Jürgen Knobloch7Medical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyMedical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyMedical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyMedical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyMedical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyDepartment of Internal Medicine II, Pneumology, Allergology and Respiratory Medicine, Bethel Teaching Hospital, 12207 Berlin, GermanyPyhrn-Eisenwurzen-Klinikum Steyr, Klinik für Pneumologie, Lehrkrankenhaus der Uniklinik Linz, Sierninger Str. 170, 4400 Steyr, AustriaMedical Clinic III for Pneumology, Allergology and Sleep Medicine, Bergmannsheil University Hospital, Ruhr-University Bochum, Bürkle-de-la-Camp-Platz 1, 44789 Bochum, GermanyIn smoking-induced chronic obstructive pulmonary disease (COPD), various comorbidities are linked to systemic inflammation and infection-induced exacerbations. The underlying mechanisms are unclear but might provide therapeutic targets. T-cell activity is central in systemic inflammation and for infection-defense mechanisms and might be influenced by comorbidities. Hypothesis: Circulating biomarkers of comorbidities modulate the activity of T-cells of the T-helper type 1 (Th1) and/or T-cytotoxic type 1 (Tc1). T-cells in peripheral blood mononuclear cells (PBMCs) from non-smokers (NS), current smokers without COPD (S), and COPD subjects (total <i>n</i> = 34) were ex vivo activated towards Th1/Tc1 and were then stimulated with biomarkers for metabolic and/or cardiovascular comorbidities (Brain Natriuretic Peptide, BNP; chemokine (C-C motif) ligand 18, CCL18; C-X3-C motif chemokine ligand 1, CX3CL1; interleukin-18, IL-18) or for asthma- and/or cancer-related comorbidities (CCL22; epidermal growth factor, EGF; IL-17; periostin) each at 10 or 50 ng/mL. The Th1/Tc1 activation markers interferon-γ (IFNγ), tumor necrosis factor-α (TNFα), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were analyzed in culture supernatants by Enzyme-Linked Immunosorbent Assay (ELISA). Ex-vivo activation induced IFNγ and TNFα without differences between the groups but GM-CSF more in S vs. NS. At 10 ng/mL, the different biomarkers increased or reduced the T-cell activation markers without a clear trend for one direction in the different categories of comorbidities or for the different T-cell activation markers. At 50 ng/mL, there was a clear shift towards suppressive effects, particularly for the asthma— and cancer-related biomarkers and in cells of S and COPD. Comorbidities might suppress T-cell immunity in COPD. This could explain the association of comorbidities with frequent exacerbations.https://www.mdpi.com/1422-0067/22/13/7187COPDcomorbiditiesT-cells |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kaschin Jamal Jameel Willem-Jakob Gallert Sarah D. Yanik Susanne Panek Juliane Kronsbein David Jungck Andrea Koch Jürgen Knobloch |
spellingShingle |
Kaschin Jamal Jameel Willem-Jakob Gallert Sarah D. Yanik Susanne Panek Juliane Kronsbein David Jungck Andrea Koch Jürgen Knobloch Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD International Journal of Molecular Sciences COPD comorbidities T-cells |
author_facet |
Kaschin Jamal Jameel Willem-Jakob Gallert Sarah D. Yanik Susanne Panek Juliane Kronsbein David Jungck Andrea Koch Jürgen Knobloch |
author_sort |
Kaschin Jamal Jameel |
title |
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD |
title_short |
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD |
title_full |
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD |
title_fullStr |
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD |
title_full_unstemmed |
Biomarkers for Comorbidities Modulate the Activity of T-Cells in COPD |
title_sort |
biomarkers for comorbidities modulate the activity of t-cells in copd |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-07-01 |
description |
In smoking-induced chronic obstructive pulmonary disease (COPD), various comorbidities are linked to systemic inflammation and infection-induced exacerbations. The underlying mechanisms are unclear but might provide therapeutic targets. T-cell activity is central in systemic inflammation and for infection-defense mechanisms and might be influenced by comorbidities. Hypothesis: Circulating biomarkers of comorbidities modulate the activity of T-cells of the T-helper type 1 (Th1) and/or T-cytotoxic type 1 (Tc1). T-cells in peripheral blood mononuclear cells (PBMCs) from non-smokers (NS), current smokers without COPD (S), and COPD subjects (total <i>n</i> = 34) were ex vivo activated towards Th1/Tc1 and were then stimulated with biomarkers for metabolic and/or cardiovascular comorbidities (Brain Natriuretic Peptide, BNP; chemokine (C-C motif) ligand 18, CCL18; C-X3-C motif chemokine ligand 1, CX3CL1; interleukin-18, IL-18) or for asthma- and/or cancer-related comorbidities (CCL22; epidermal growth factor, EGF; IL-17; periostin) each at 10 or 50 ng/mL. The Th1/Tc1 activation markers interferon-γ (IFNγ), tumor necrosis factor-α (TNFα), and granulocyte-macrophage colony-stimulating factor (GM-CSF) were analyzed in culture supernatants by Enzyme-Linked Immunosorbent Assay (ELISA). Ex-vivo activation induced IFNγ and TNFα without differences between the groups but GM-CSF more in S vs. NS. At 10 ng/mL, the different biomarkers increased or reduced the T-cell activation markers without a clear trend for one direction in the different categories of comorbidities or for the different T-cell activation markers. At 50 ng/mL, there was a clear shift towards suppressive effects, particularly for the asthma— and cancer-related biomarkers and in cells of S and COPD. Comorbidities might suppress T-cell immunity in COPD. This could explain the association of comorbidities with frequent exacerbations. |
topic |
COPD comorbidities T-cells |
url |
https://www.mdpi.com/1422-0067/22/13/7187 |
work_keys_str_mv |
AT kaschinjamaljameel biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT willemjakobgallert biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT sarahdyanik biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT susannepanek biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT julianekronsbein biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT davidjungck biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT andreakoch biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd AT jurgenknobloch biomarkersforcomorbiditiesmodulatetheactivityoftcellsincopd |
_version_ |
1721299218718523392 |